Karyopharm Therapeutics | KPTI - Trade Debtors


Karyopharm Therapeutics reported $23.36M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Abbott USD 11.22B 655M Mar/2026
Amgen USD 10.23B 1.09B Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
GlaxoSmithKline GBP 8.07B 137M Jun/2026
Incyte USD 1.13B 73.7M Jun/2026
J&J USD 22.54B 1.21B Mar/2026
Karyopharm Therapeutics USD 23.36M 2.82M Mar/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Merck USD 12.21B 435M Mar/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Novartis USD 9.85B 252M Jun/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.19B 19M Jun/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Takeda JPY 956.14B 79.79B Jun/2026
Tectonic Therapeutic USD 0 270K Dec/2023
TG Therapeutics USD 392.05M 86.42M Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Xencor USD 42.23M 30.23M Jun/2026